Bangalore (Reuters)-The Serum Institute of India, the world’s largest vaccine producer, said on Thursday that it has produced 40 million doses of AstraZeneca’s potential COVID-19 vaccine, and as they are all seeking regulatory approval, they will soon Will start to produce Novavax competitors.
Serum said it has recruited 1,600 participants in India to participate in AstraZeneca’s late-stage trials. AZN.L Candidate, and also plans to seek regulatory approval to conduct late-stage trials for Novavax NVAX vaccine.
Serum said that the AstraZeneca vaccine co-developed by the University of Oxford is the most advanced vaccine tested in humans in India, adding that the company and the Indian Council of Medical Research (ICMR) will provide the vaccine “as soon as possible”
Both Serum and ICMR representatives declined to comment on whether the 40 million doses of AstraZeneca vaccine are only available in India.
Serum said that the federal government agency ICMR funded the clinical trial cost of AstraZeneca vaccine. The company and ICMR are currently conducting mid-term clinical trials of shots in 15 centers in India.
The news came when India was the second worst-hit country in the world. Coronavirus infections in India reached 8.68 million on Thursday, and the death toll increased to more than 128,000.
India also has at least two locally developed COVID-19 vaccine candidates under development, and the local drugmaker Dr. Reddy’s laboratory Reddy The candidate vaccine is being tested in Russia.
Earlier this week, Pfizer Polytetrafluoroethylene And its partner BioNTech 22UAy.DE According to preliminary test results, their candidate vaccine has been proven to be more than 90% effective. Pfizer said it will work to strengthen contacts with the Indian government to provide potential vaccines in India.
Reporting by Sachin Ravikumar; Editing by Tom Hogue and Michael Perry